Article

Drugmaker pulling the plug on Phospholine Iodide

Author(s):

Citing an unstable supply chain, Pfizer is discontinuing the ophthalic drops.

In recent years, intermittent shortages of Phospholine Iodide (echothiophate iodide) ophthalmic drops have created issues for ophthalmologists, and the American Academy of Ophthalmology, American Glaucoma Society and the American Association for Pediatric Ophthalmology and Strabismus have often stepped up to work with Pfizer to correct the issue.

Ultimately, an unstable supply chain proved to be too great of a hurdle, and Pfizer announced recently it will discontinue the drops. The medication is used to treat IOP in glaucoma patients and also is prescribed for other issues, such as accommodative esotropia. There is no generic equivalent available, and Pfizer is the only manufacturer. 

In a legal notice, Pfizer has announced that Phospholine Iodide will not be available after May 1, with the expiration date on what supply is left is June 30, 2021.

The drugmaker said its decision was not based on safety, but on an unstable supply chain that has created shortages in recent years.

“We regret to inform you that after careful consideration Pfizer has made the decision to discontinue Phospholine Iodide,” the company said in a statement. “The manufacturing of Phospholine Iodide is complex and requires a series of external partners. Over the years, the supply chain has become increasingly unstable, leading to multiple stock-outs.”

According to the company, a limited supply of Phospholine Iodide will remain available through May 1, 2021. It may be ordered by calling Pfizer customer service at 1 800-533-4535 (option 4) and requesting a drop shipment.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.